BMS Combo Would Gain Heft in Melanoma Space, Say Analysts

Tuesday, June 23, 2015

Source: Medical Marketing & Media

The dominant treatment in the melanoma marketplace could end up being not one but two drugs—the combination of Bristol-Myers Squibb immuno-oncology products Opdivo and Yervoy—according to market research firm GlobalData, based on data the firm saw at the American Society of Clinical Oncology's annual meeting.

View All News »